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Women who have an inherited mutation in the BRCA1 or BRCA2 genes have a substantial
increased lifetime risk of developing epithelial ovarian cancer (EOC), and epidemiological
factors related to parity, ovulation, and hormone regulation have a dramatic effect on the risk
in both BRCA mutation carriers and non-carriers. The most common and most aggressive
histotype of EOC, high-grade serous carcinoma (HGSC), is also the histotype associated
with germline BRCA mutations. In recent years, evidence has emerged indicating that the
likely tissue of origin of HGSC is the fallopian tube.We have reviewed, what is known about
the fallopian tube in BRCA mutation carriers at both the transcriptional and translational
aspect of their biology. We propose that changes of the transcriptome in BRCA heterozy-
gotes reflect an altered response to the ovulatory stresses from the microenvironment,
which may include the post-ovulation inflammatory response and altered reproductive
hormone physiology.
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INTRODUCTION
In 2013, about 22,240 women in the United States would have
been diagnosed with invasive epithelial ovarian cancer (EOC)
and an estimated 14,000 women with EOC would have died
(1). There are five major histotypes of EOC and they are dis-
tinct epidemiologically, phenotypically, and molecularly, namely:
mucinous, endometrioid, clear cell, low-grade serous, and high-
grade serous carcinoma (HGSC). Of these, HGSC is the most
prevalent histotype in the Western Hemisphere, the most lethal,
typically is diagnosed at an advanced stage, and there are no effec-
tive cancer screening strategies. More than 75% of women with
this diagnosis will succumb to the disease after combined first line
treatment, which includes surgery and adjuvant platinum-based
chemotherapy, with a 5-year survival of <30% (1, 2). HGSC is
a genetically unstable tumor, characterized by a varied histomor-
phology unified by marked pleomorphism, a high mitotic rate,
and biomarker expression reflective of the most common molec-
ular alterations. The latter includes the near ubiquitous presence
of a mutation in the tumor suppressor p53 (TP53), resulting in
either over accumulation of p53 protein by immunohistochem-
istry (missense – 60% of analyzed cases) or complete loss of protein
expression (frameshift/splicing junctions/non-sense – 39% of ana-
lyzed cases) (3). Mutations of p53 are present in early stage HGSC,
and mutant TP53 is likely an essential driver mutation required for
the early pathogenesis of HGSC (4). Other recurrent mutations in
HGSC are infrequent, but most prominently include BRCA1 and
BRCA2, with BRCA germline mutations seen in 13–16% (5), and
somatic mutations seen in about 6% of cases.
High-grade serous carcinoma is the predominant histotype
associated with hereditary breast-ovarian cancer (6, 7). Women
with inherited mutations of BRCA1 or BRCA2, have a life-
time risk of 40–60% (BRCA1) and 11–27% (BRCA2) (8–12).
Women known to be at increased genetic risk based on family
history and/or genetic testing are offered risk-reducing salpingo-
oophorectomy (RRSO), which reduces the risk of malignancy by
up to 96% (13, 14) and is usually performed after completion of
childbearing and while the woman is still pre-menopausal (13, 15).
An unexpected finding on histopathology review of the resected
fallopian tubes in this population was the presence of clinically
undetected, occult carcinomas in the fallopian tubes, a tissue pre-
viously thought to develop carcinomas only rarely. These were seen
more frequently than in the ovarian tissues (16). This discovery
was followed by careful review of the fallopian tube tissues, and
subsequent studies have reported histological lesions purported to
be HGSC precursors in the fallopian tube epithelium – these had
not been found in the genetic high-risk ovarian tissues (16–22).
Hence, detailed histo-pathological examination of the resected
ovaries and fallopian tubes in BRCA mutation carriers has led
to a radical change in existing paradigms of serous carcinogen-
esis. Because loss of BRCA function is frequent in HGSC, study
of the effect of BRCA, including heterozygosity/haploinsufficiency
and loss of function in the fallopian tube epithelium prior to the
development of HGSC, offers opportunities to better understand
HGSC pathogenesis, and should lead to the development of novel
and more effective preventative, and possibly, screening strategies.
BRCA1 AND BRCA2 AND HIGH-GRADE SEROUS CANCER
Molecularly, the breast cancer susceptibility genes (BRCA) BRCA1
and BRCA2 can sense DNA damage and are involved in DNA
repair via interactions with RAD51 (23–25); these three pro-
teins are essential for genomic stability in normal cells predom-
inantly through the homologous recombination pathway (HR)
(26). BRCA1 is a known modulator of the cell-cycle at the G2-M
checkpoint (27) operating through co-activation with p53 (28)
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and has also been shown to epigenetically regulate the onco-
genic microRNA 155 and to maintain heterochromatin struc-
ture via ubiquitylation of H2A (29, 30). Inherited mutations in
BRCA1/BRCA2 confer an autosomal-dominant effect and range
from being deleterious to protein function to being of uncertain
significance (31).
Breast cancer susceptibility gene mutation carriers develop can-
cers in hormonally regulated tissues, most frequently in breast and
ovarian/tubal tissues, but a unifying mechanism of early malig-
nant transformation in these tissues is not known. The BRCA
associated carcinomas share some common features including a
high-grade phenotype, frequent mutations of TP53, and other
copy number landscape features like Cyclin-E amplification and
deletion of Rb (32). Altered BRCA function in HGSC does not only
occur in the setting of hereditary disease. Dysfunction of BRCA1
or BRCA2 is prevalent in patients with HGSC via 6% somatic
mutations (5, 33–35); 13–31% promoter hypermethylation (5,
36–38); 7.9–17% amplification of EMSY (5, 39, 40); or 13.2%
promoter hypermethylation of FANCF (41). The sum of these
genomic alterations predominantly in the HR pathway of HGSC
has led to determining the “BRCAness” profile in patients (42, 43).
BRCAness is defined as a phenotype determined by deficiencies in
the double strand break (DSB) repair pathways, as seen in tumors
associated with germline BRCA mutations and a subset of spo-
radic high-grade serous ovarian cancers. An understanding of the
early molecular changes in genetic high-risk patients may therefore
also be of importance to many of the sporadic cancers. Patients
with the BRCAness profile most likely will benefit from treatments
affecting other DNA repair pathways – specifically PARP inhibitors
(43). Outcome data suggests that patients with loss of function of
BRCA have improved survival, but recently a study by McLaughlin
and colleagues determined that although BRCA mutation carri-
ers have a short-term (up to 5 years post diagnosis) benefit and
response to platinum-based therapy, there is a lack of long-term
(up to 10 years post diagnosis) survival benefit (44). Most promis-
ingly, the loss of function of BRCA1/BRCA2 whether genetic or
epigenetic by mechanisms including promoter hypermethylation,
offers the possibility of improved therapies with poly (ADP-ribose)
polymerase (PARP) inhibitors (43).
BRCA1 AND BRCA2 AND THE FALLOPIAN TUBE EPITHELIUM
The mechanisms underlying malignant transformation in these
estrogen responsive tissues are poorly understood, but likely
involve loss of heterozygosity of the remaining wild type BRCA
allele (45) in addition to inactivation of p53. During ovulation,
it is thought that high levels of reactive oxygen species (ROS) are
released via the cytokine surge accompanied with lysis of the ovum
(follicular fluid). These species have a complex role in the devel-
opment and progression of cancer (46). The high ROS levels are
likely a source of “carcinogens,” which cause DNA damage in the
FIGURE 1 | (A) FTE cell lines were established to study gene specific effects
in relation to BRCA abrogation in BRCA mutation carriers and other
aberrations identified in the precursor lesions and malignant lesions observed
in situ in the distal end of the FTE. (B) FTE cell lines established from normal
FTE tissue were infected with a short hairpin to BRCA1 (shBRCA1). The FTE
cells with BRCA loss have the classic phenotype of senescent cells – flat,
enlarged, and vacuolated. PCR confirmed knockdown. (C) In the p53 signature
in the normal FTE, low proliferation, normal cell polarity, and over-expression
of p53 are observed. Thus far, BRCA loss-of-heterozygosity (in mutation
carriers), decrease in Rb, and increase in p16 (immunohistochemistry), CCNE1
amplification, and over-expression (FISH and immunohistochemistry); hTERT
amplification (FISH), common in HGSC are also observed in the STIC lesions.
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FTE and possibly contribute to the mutations in TP53. In nor-
mal cells repair of DNA damage results in cell-cycle arrest through
senescence or death as demonstrated in epithelial cell lines estab-
lished from FTE (Figures 1A,B). This process must be overcome
for transformation to occur (47). In high-grade serous ovarian
cancer cells, 99% of tumors have a mutation in TP53, indicat-
ing that the mutation likely occurs early in disease progression
(3, 5). This combination – TP53 mutation and BRCA loss, can
provide an escape or by-pass through the cell-cycle checkpoints
to allow additional cancer promoting mutations, amplifications,
or deletions. Therefore, BRCA1/BRCA2 deficient cells [lacking
ATM/ATR-CHK2 pathway (48)] cannot sense DNA damage in
order to transduce signal to the already TP53 mutant cells. In this
setting, cells can overcome the barriers for cell-cycle progression,
however this may not be sufficient for transformation into a tumor.
In normal cells of mutation carriers, only one allele is mutated,
and BRCA1 function is presumed to be intact. This may however
not be true, as evidence in support of BRCA1 haploinsufficiency
accumulates. For example, in normal human mammary epithe-
lial cells from BRCA1 heterozygotes, DNA homologous repair is
suppressed (49). BRCA1 haploinsufficiency may be an early but
not a sufficient step of BRCA1-mediated breast carcinogenesis. In
HGSC, it is uncertain when during malignant transformation of
FTE, loss of BRCA1 function occurs. In contrast to breast cancer,
it seems likely altered p53 function resulting from p53 mutation
occurs prior to loss of the wild type BRCA1 allele in FTE trans-
formation. Loss of BRCA1 protein and loss of heterozygosity is
seen once malignant transformation has occurred but, according
to Norquist et al. not in early precancerous lesions (45). The p53
mutation is thought to promote genomic instability, a hallmark
of high-grade serous cancer, and cooperates with BRCA1 loss or
a dysfunctional HR pathway to mediate the extent of genomic
amplifications and gains so commonly seen in HGSC.
p53 SIGNATURE AND SEROUS TUBAL INTRAEPITHELIAL CARCINOMA
For many years, in the absence of a reproducible histological
precursor lesion of HGSC, the cell of origin was presumed to
be the ovarian surface epithelium (OSE), a modified type of
mesothelium. Detailed histo-pathological examination of tubal
epithelia (FTE) in the genetically high-risk population under-
going risk-reducing surgery has led to the discovery of putative
cancer precursor lesions in the fallopian tube, some of which, i.e.,
the p53 signature – described as a string of 10–12 histologically
normal secretory (non-ciliated) cells expressing the TP53 protein
with a low proliferation rate (Ki67) (50), are found with a sim-
ilar frequency in BRCA mutation carriers and non-carriers. Two
independent studies reported similar findings albeit at different
frequencies of p53-signatures between the two study cohorts: 11
and 19% (51) and 24 and 33% (52) in women with germline BRCA
mutations and population control, respectively. The cells within
the p53 signature are Pax8 positive and up-regulate phosphory-
lated – γH2AX, reflective of concomitant DNA damage. Women
with an inherited mutation in the TP53 gene – the Li Fraumeni
syndrome, have an increased risked in developing between five and
six different cancers (breast, brain, soft tissue sarcomas, and blood
cancers) throughout their lifetime (52). These patients, however,
do not have an increased incidence of developing high-grade
serous ovarian cancer, but have an increased number of p53-
signatures compared to the rest of the population. In addition,
in a small epidemiological study, p53-signatures were not associ-
ated with the traditional risk factors of breast-feeding, parity and
tubal ligation, bringing into questions whether the p53 signature is
a true cancer precursor lesion (53). However, it can be said that loss
of normal p53 function is necessary, but not sufficient to promote
carcinogenesis of epithelial cells in the distal fallopian tube.
Occult invasive carcinoma and serous tubal intraepithelial car-
cinomas (STICs) were identified in the fallopian tubes of mutation
carriers undergoing risk-reducing surgery, with an incidence of
about 4–6% for occult cancers (16, 54, 55). Importantly, STICs are
found not only in BRCA mutation carriers, but are also detected
in about 60% of sporadic HGSC (19, 56). STICs are thought to
have progressed from the p53 signature and are characterized as
being highly proliferative (>10% Ki67) (57), show loss of apical to
basal nuclear polarity and, in common with HGSC, demonstrate:
over-expression of cyclin-E (58), amplification of hTERT (59), p16
over-expression (CDKN2A), loss of Retinoblastoma protein (Rb)
(60), and up-regulation of the PI3K pathway (61) (Figure 1C). In
mutation carriers undergoing RRSO, STICs were identified in at
least 8% of cases, a higher frequency than seen in patients at low
genetic risk (51, 52, 62, 63).
Like HGSC, the frequency of STIC lesions increases with age,
is increased in BRCA1/2 mutation carriers, and is lower with oral
contraceptive use, all features providing further evidence that STIC
is an immediate precursor of invasive and clinically detectable
carcinoma (53). These intraepithelial carcinomas should not be
considered as only in situ carcinomas, because in at least some
cases while tumor cells do not invade underlying stroma, they can
detach, and because of the accessibility of the ipsilateral ovary and
other peritoneal surfaces to the tubal fimbria, cells may implant
and establish tumor growth in other sites. Currently, little evidence
exists that patients with only a diagnosis of STIC require adjuvant
therapy (64). Further molecular and genetic characterization of
STIC is ongoing, but molecular evidence to date indicates that
alterations commonly seen in HGSC are also present in STIC.
Lesions that precede the STIC, are not well characterized, but
currently the term serous tubal intraepithelial lesion (STIL) is
given to lesions according to criteria recommended in a pro-
posed diagnostic algorithm. The STIL is described as a lesion,
which has abnormal p53 expression by immunohistochemistry
and increased proliferation relative to background (tubal epithe-
lium) but <10% Ki67 positive. (57, 65). Ongoing studies are
required to further define this lesion as current definitions lack
diagnostic reproducibility. Other than the changes associated with
the p53 signature, molecular changes which precede the estab-
lishment of an intraepithelial cancer are not well documented.
Indeed, these lesions are uncommon, and identified with poor
reproducibility.
NORMAL TUBE EPITHELIUM IN BRCA MUTATION CARRIERS
Hormonally responsive epithelia, from breast, ovary, and fallopian
tube, are the preferential targets for malignant transformation in
BRCA1/2 mutation carriers and the mechanisms are increasingly
being determined primarily through studying breast epithelia (66).
Evidence is emerging nonetheless that morphologically normal
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fallopian tube epithelium from women with inherited mutations,
differs significantly from the tubal epithelium of women at low
cancer risk. Differences in morphologically normal epithelium
from BRCA mutation carriers have shed light into the effects of
heterozygosity and predisposition to high-grade serous ovarian
cancer. In five previous reports, we have used morphologically
normal fallopian tubal epithelium from BRCA1 and BRCA 2
(FTE-BRCA) mutation carriers and non-mutation carriers (FTE-
normal), to compare gene expression profiles to identify differ-
ences conferred by the presence of one mutant allele (67–71). In
addition to family history, a major risk factor is number of life-
time ovulations, and oral contraception use and increase in parity
lead to a reduction in EOC risk (72). The formerly prevailing inces-
sant ovulation hypothesis first described by Fathalla suggested that
continuous disruption and surrounding inflammation of the OSE
during ovulation led to the development of carcinoma in the ovary
(73). It is likely however that the effects of ovulation are still impor-
tant in malignant transformation, but the effects are on fimbrial,
not ovarian, epithelium.
Therefore in the design of experiments, the patient tissues
analyzed were controlled for not only age and menopause but
also stage in the ovarian cycle – follicular (proliferative phase)
and luteal (post-ovulatory phase) at the time of surgery (70,
71). We showed that the BRCA mutation in morphologically
normal fallopian tube epithelium confers a significantly altered
gene expression signature. Some of these altered pathways include
the TGF-β pathway, MAP kinase pathway, the adipokine signal-
ing pathway, inflammatory pathway, and the p53-signaling path-
way (70, 71). In particular genes involved in DNA damage and
inflammation were validated as both having transcriptional and
translational differential expression in the normal fallopian tubes
(ampulla and fimbria) of BRCA mutation carriers. Namely, DAB,
NAMPT, C/EBP-δ, GADD45β, and NF-κB are genes involved in
the Jak/Stat, DNA damage, and TGF-β pathways and are promi-
nently differentially expressed in mutation carriers and in HGSC.
In these studies, we noted, that BRCA mRNA levels were not sub-
stantially different between carriers and non-carriers, indicating
that the wild type allele was still intact. In an independent study,
Press et al. reported significant differences in proliferation and
cell-cycle regulation in BRCA mutation carriers (with and without
occult carcinoma) (74).
We subsequently analyzed the distal end FTE (the fimbria),
the anatomical region of highest risk and the ampulla for: (1)
the presence of immune infiltrates (CD3+ and CD8+ lympho-
cytes and CD68+ macrophages) and (2) the proliferation status of
FTE cells in both BRCA mutation carriers and population control.
This study although not exhaustive, revealed that independent of
BRCA mutation status: (1) macrophages were more prevalent in
the luteal phase than the follicular phase of the ovarian cycle and
(2) proliferation in FTE cells is predominantly an effect of the
follicular phase rather than BRCA mutation status in histologi-
cally normal tissue (Figure 2). However, a small subset of FTEs
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FIGURE 2 | (A) A trend is observed, where in some cases the ratio of
CD68+ macrophages to CD3+ lymphocytes increases from the normal FTE
to STIC to the concomitant cancer. (B) Immunohistochemistry of CD3+
and CD68+ in normal FTE, STIC (same STIC as depicted in Figure 1), and
HGSC. (C) High-grade serous carcinoma is the most common type of
ovarian cancer and women with BRCA1/2 mutations have a 40–60%
increased lifetime risk for developing the disease. Interrogation of the
normal FTE microenvironment demonstrates that there is no inherent
difference in proliferation or in some immune cell populations within the
histological normal tissue in FTE of BRCA1/2 mutation carriers compared
to the normal population. An increase in proliferation and lymphocytes and
macrophages occurs later in tumor progression when the FTE have
already lost cell-cycle progression barriers and there is histological
evidence of a precursor lesion.
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from BRCA2 mutation carriers had a diffuse increase in prolifera-
tion in the absence of histological lesions, but overall there was no
statistical difference in proliferation compared to the control tis-
sues (68). Therefore, we propose that chronic inflammatory states
through cyclical ovulation and the presence of a mutated BRCA
allele can predispose the normal FTE to develop lesions, which
may lead to serous carcinoma. We hypothesize that this occurs
through deregulation of DNA damage response genes and syner-
gistically through up-regulation of cytokines, pro-inflammatory,
and proliferation genes. It is possible that changes demonstrated
in gene expression profiles reflect the earliest alterations in cancer
development,and/or that they are markers of increased cancer risk.
OVULATORY CYCLE AND BRCA IN THE FALLOPIAN TUBE
EPITHELIUM
Most women who develop sporadic cases of EOC are peri- or post-
menopausal with a mean age of 58 years (75); however, BRCA1
mutation carriers develop the disease earlier with a mean age of
51 years and BRCA2 mutation carriers a bit later, with a mean
age of 57 years (75–78). In addition to family history, the major
epidemiological risk factors for EOC indicate a strong influence
of reproductive factors and reproductive hormones. Risk factors
including nulliparity, early age of menarche, late age of menopause,
hormone replacement, obesity, and protective factors including
oral contraceptive use, indicate an association with increased life-
time ovulations and/or greater lifetime exposure to estrogen. A
higher risk of ovarian cancer has been reported with cyclical use
of hormone replacement therapy rather than continuous use or
any use of estrogen or progestin after menopause (79) for both
BRCA mutation carriers and non-carriers (72).
The influence of sex hormones on tubal/ovarian malignant
transformation is not well understood, but seems likely that the
BRCA1/2 associated changes in reproductive hormones and their
receptors play a role in tumor formation, in addition to the alter-
ations in DNA damage repair. BRCA1/2 mutation carriers do not
have menopause at an early age (80). Higher circulating estradiol is
associated in the general population with a pre-menopausal breast
cancer risk, and BRCA2 carriers with breast cancer do have higher
estradiol levels in the early follicular phase, but a similar associa-
tion with circulating progesterone is not seen. It has recently been
shown that mutation carriers have higher levels of both estradiol
and progesterone during the luteal, not follicular phase, leading
the investigators to suggest a defect in steroid hormone regulation
potentiates the mutagenic effect of the BRCA mutation (80, 81). In
mice, it has been shown that granulosa cells in mice lacking func-
tional Brca1 are exposed to increased estradiol stimulation due
to a combination of a prolonged pre-ovulatory (proestrus) phase
of the estrus cycle and increased levels of circulating estradiol. In
addition, estrogen biosynthesis in granulosa cells is altered in mice
not only with a deleterious homozygous mutation but also in mice
with a heterozygous Brca1 mutation (82), a state which mimics
the BRCA1 mutation carriers. This provides further evidence that
heterozygous BRCA1 mutations are associated with phenotypic
changes.
The role of estrogen and progesterone in early malignant trans-
formation in the FTE is not yet well understood. Estrogen mediates
its action primarily through the estrogen receptor (ERα and ERβ).
Estrogen stimulates the expression of a number of genes that
promote cell proliferation, motility/invasion, and inhibition of
apoptosis namely: IL6, TGF-α, EGF, PI3K/Akt, IFG-1, and Bcl-
2 (which is predominantly expressed in secretory FTE) (78). The
estrogen dominant phase during the ovarian cycle is the follicu-
lar (or proliferative) phase and is associated with an increase in
FTE proliferation (68) and promotion of ciliogenesis (83). In con-
trast, progesterone receptor activity is associated with a decrease
in cell proliferation (68), an increase in apoptosis, possibly medi-
ated through the down-regulation of CDK1/cyclin B1 complex,
which impedes the G2/M transition. Conversely, in the breast, it is
known that progesterone elicits proliferation through Cyclin D1
in PR positive cells (a cell intrinsic autocrine loop) and in PR
negative cells via NF-κB ligand RANKL secretion (paracrine) (84,
85). Progesterone mediates its activity through the progesterone
receptors (PR-A and PR-B are isoforms with differential transla-
tional start sites). On progesterone binding PR translocates to the
nucleus to direct an antagonist effect on ERα signaling. Both cili-
ated and secretory FTE cells express the estrogen and progesterone
receptors (69) and undergo cyclic changes in growth and differ-
entiation throughout the ovarian cycle; these changes are most
evident in the fimbriae (86) the “high-risk” zone of the tube (86).
The fallopian tube epithelia in the luteal phase of the ovarian cycle
have significantly lower levels of the progesterone (PR-A) (69) and
estrogen [ERα) receptors (87)] (Figure 3).
During ovulation, there is a surge of estrogen released into the
FTE microenvironment with release of follicular fluid, which con-
tains high estrogen levels. This effect might be exacerbated (88)
in fallopian tube epithelia of BRCA mutation carriers under the
direct influence of the relevant DNA repair pathways, which are
potentially dysfunctional. In addition to its well-established roles
in regulation of DNA damage response, the Brca1 protein inhibits
ERα transcriptional activity through direct action of BRCA1 and
ERα proteins and down-regulation of p300, a nuclear receptor
co-activator (89). Brca1 protein also regulates estrogen receptor
action through suppression of aromatase, the enzyme required
for estrogen biosynthesis from androgen. Gorrini et al. recently
showed that an antioxidant estrogen target gene – Nrf2, can medi-
ate a pro-survival effect in the absence of normal BRCA1 protein,
in which cells would otherwise undergo cellular senescence or
death (66). BRCA1 loss in mammary epithelium therefore alters
the estrogenic growth response, and increased estrogen signaling
collaborates with Brca1 deficiency to accelerate preneoplasia and
cancer development. Although this has not been tested in FTE,
this is an interesting concept that may have implications in serous
carcinogenesis.
A decrease in the transcription and translation (by immuno-
histochemistry) of PR-A and PR-B were observed in the luteal
phase of both BRCA mutation carriers and population control
(69). PR gene signatures were identified in a subset of FTE cases
in the luteal phase that had a similar profile to HGSC, however,
PR target genes were not differentially expressed between BRCA
mutation carriers and controls (69). In HGSC, PR expression is
predominantly decreased/lost, a finding in 70–80% of patients
(69, 90). PR expression in greater than 50% of tumor cells has
been recently reported to have an overall survival benefit, and this
benefit was independent of germline BRCA1/2 mutation status
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FIGURE 3 | (A)The different phases of the ovarian cycle in pre-menopausal
women is the dominant effect on gene transcription in epithelia of normal
fallopian tubes in BRCA mutation carriers. Translationally, there are more
cells expressing ER, PR in the follicular phase of the cycle independent of
mutation status. Similarly there are significantly more cells responding to
the mitogenic effects of estrogen observed by an increase in proliferation.
In the post-ovulatory phase, there is an observed increase in macrophages
in both BRCA mutation carriers and non-carriers. (B) Representative images
of proteins expressed in normal FTE-BRCA and FTE-normal that seemingly
look and express these proteins similarly. Underlying these morphological
similarities is a potential haploinsufficiency predisposing FTE-BRCA to
cytotoxic stresses.
(90). In contrast, 70–80% of HGSC patients express ERα (>50%)
but ER expression has not been shown to be associated with a
significant recurrence free progression or survival benefit (87, 90).
Epidemiological data indicate that HGSC risk is closely linked
to the events of ovulation, and these risk factors and protective
factors for the most part are true for both sporadic and heredi-
tary HGSC. In addition, evidence suggests that the risk for EOC
increases during the pre-menopausal years, and that menopause is
protective against ovarian cancer (91). The role of sex hormones
in ovarian cancer development is complex however, and early
evidence suggests that endocrine function may differ in BRCA1
heterozygotes. The mechanisms of altered hormone function and
impact of genetic mutations on endocrine production and recep-
tivity in the FTE of high-risk patients is not yet understood, but
it remains possible that the underlying growth stimulatory effects
of estrogen are altered in a BRCA mutation carrier.
CONCLUDING REMARKS
In conclusion, there are many epidemiological studies linking ovu-
lation, parity, and hormonal use to the development of EOC.
About 60% or more of HGSC demonstrate a BRCAness profile
predominantly through a dysfunctional homologous recombi-
nant pathway, which synergizes with the ubiquitousness of the
p53 mutations found amongst these tumors. In the normal fal-
lopian tube of BRCA mutation carriers, transcription profiles
reveal predominant differences in DNA damage and inflammation
pathways. Interestingly and may be not surprisingly, FTE-BRCA
samples are transcriptionally indistinguishable from FTE-normal
samples when transcription profiles undergo unsupervised hier-
archical clustering (70). Instead, the sample alignment is depen-
dent on the estrogen or progesterone dominant phases of the
ovulatory cycles, lending biological support to the known epi-
demiological risk factors and providing evidence for a possible
haploinsufficiency of the functional allele in the normal FTE.
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